St Francis Medical Institute

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis3 trials
• Asthma2 trials
• Obstructive sleep apnoea2 trials
• Atopic dermatitis (eczema)1 trial
• Bronchiectasis1 trial
• COPD1 trial

Phase

• Phase 36 trials
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Apnimed2 trials
• Eli Lilly and Company1 trial
• Regeneron Pharmaceuticals1 trial
• Target PharmaSolutions, Inc.1 trial

Running trials

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

  NCT06572228· Phase 4· Regeneron Pharmaceuticals· Source

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Apnimed· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obstructive sleep apnoea1 recruiting

Closed trials

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Completed

  Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

  NCT05811247· Phase 3· Apnimed· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study of Patients With Chronic Disease

  NCT04263727· Target PharmaSolutions, Inc.· Source